Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
申请人:4SC AG
公开号:EP2100894A1
公开(公告)日:2009-09-16
The invention relates to pyridopyrimidinone compounds according to formula (I),
wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of Plk1.
[EN] PYRIDOPYRIMIDINES AS PLK1 ( POLO-LIKE KINASE) INHIBITORS<br/>[FR] PYRIDOPYRIMIDINONES COMME INHIBITEURS DE PLK1 (KINASE DE TYPE POLO)
申请人:4SC AG
公开号:WO2009112524A1
公开(公告)日:2009-09-17
The invention relates to pyridopyrimidinone compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of Plk1.
[EN] HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS<br/>[FR] PYRIMIDODIAZÉPINES À SUBSTITUTION HALOGÉNO EN TANT QU'INHIBITEURS DE PLKL
申请人:HOFFMANN LA ROCHE
公开号:WO2009153197A1
公开(公告)日:2009-12-23
The present invention provides PLK1 inhibitor compounds of formula (I): useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula (I).